Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by Pareto8020on May 03, 2021 1:19pm
271 Views
Post# 33114955

Here goes Howard.....Back peddle Back peddle

Here goes Howard.....Back peddle Back peddleAnd of course they have stretched out the milestones once again.  Unbelievable.  

https://www.sironabiochem.com/wp-content/uploads/2021/05/SBM-Investor-Presentation-May2021.pdf

Sirona anticipates achieving the following milestones • within the next 3 months: • Finalize due diligence and agree on terms with new organization in China • Complete an additional licensing agreement for the SGLT2 inhibitor in new markets • Secure non-dilutive funding through anticipated collaborations • Finalize Tinyi agreement • Complete Phase I clinical trial in China for the SGLT2 Inhibitor and advance to Phase II •

within the next 6 months: • Scale-up batch of lead anti-aging compound • Complete safety studies for anti-aging compound in preparation for clinical study •

within the next 12 months: • Enter clinical trial for anti-wrinkle compound • Develop new anti-viral compounds and advance them into preclinical studies
<< Previous
Bullboard Posts
Next >>